HLA-C and neoplasm: Actually, according to the findings of numerous research reports, the expression of MHC on tumor cells serves as an effective surrogate indicator for the general immunogenicity of the tumor and also a predictive indicator for immunotherapy response55. As shown in the results of two distinct clinical trials, CheckMate 064 and CheckMate 069, attenuated expression of tumor HLA class I molecule (≤ 30%) was linked to an absence of response to ipilimumab, while increased expression of tumor HLA class II molecule (> 1 percent) was associated with greater tumor responsiveness to nivolumab56.